This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
CARDIO-ONCOLGY BACKGROUNDSurveillance system based on heart failure symptoms
and LVEF alone are not enough to protect cancer patients from irreversible heart damage
• A new approach to patient management and disease prevention encourages a multidisciplinary Cardio-Oncology team be used to detect and prevent cardiotoxicity long before LVEF drops or symptomatic heart failure is detected
Cardinale & Cipolla, 2016, Luis Zamorano, et al, 2016 & Plana et al., 2014
CARDIO-ONCOLOGY BACKGROUNDCardio-Oncology is a new subspecialty of cardiology that
promotes collaborative efforts between cardiology and oncology providers to prevent and manage the cardiotoxic effects of cancer
therapy and increase survivability of cancer patients
Barros‐Gomes, et al, 2016, Hermann et al, 2014, Sulpher, et al, 2015
Evidence suggests clinical assessment of cardiac risk before cancer therapy would support cardiotoxicity prevention, treatment
planning, and surveillance of cardiac function before, during, and after treatment
• Understand individual risk • Encourage collaboration between providers • Develop future protocols• Assist in determining dose and duration of treatment, frequency of cardiac monitoring• Inform clinicians when to initiate cardio-protective treatments • Supports patient-centered care
Currently there are proposed operational models but no formal clinical guidelines
Ezaz, Long, Gross, & Chen, 2014, Hermann et al, 2014Shelburne, et al, 2014, & Sulpher, et al, 2015b
Who are “High Risk” for cardiotoxicity?Traditional cardiovascular risk factors
– History of heart failure (LVEF <55%)– Older age (>60) or post-menopausal– Previous coronary disease– Obese, BMI>35– Diabetes– Hypertension– Smoking
Clinical Risk Factors– Prior anthracycline or radiation therapy– Current cancer therapy that demonstrates a >3% incidence of cardiotoxicity at
normal dose ranges (i.e. Doxorubicin, daunorubicin, trastuzumab etc.)
PREVENTION: MANTICORE Results• Perindopril and bisoprolol were well tolerated in patients with
HER2-positive early breast cancer who received trastuzumab and protected against cancer therapy–related declines in LVEF;
• Decline in LVEF (via cMRI) 5% with placebo, 3% with ACEi, 1% BB.
• LV Dysfunction noted in 20% in placebo, 3% ACEi or BB
Trastuzumab therapy was interrupted in 30% placebo and only 10% ACEi & BB groups.
Pituskin et al, 2017
PREVENTION: PRADA Trial• The goal of the trial was to evaluate treatment with a beta-blocker
and/or angiotensin-receptor blocker (ARB) among patients with breast cancer undergoing anthracycline chemotherapy.
• Women with breast cancer undergoing anthracycline chemotherapy with or without trastuzumab and/or radiation were randomized by 2X2 factorial design to metoprolol succinate (target
dose 100 mg daily) versus placebo, and to candesartan (target dose 32 mg daily)
versus placebo. The duration of the study medication ranged from 10-61 weeks.
In patients treated for early breast cancer with adjuvant anthracycline-containing regimens with or without trastuzumab and radiation, concomitant treatment with candesartan provides protection against early decline in global left ventricular function
Cardiology Manages & Monitors Patient for Adverse Cardiac
Events
Cardiology Collaborates Oncology to Optimize
Treatment
Continue to Monitor & Manage
Adverse Cardiac Event
YES
YES
NO
NO
ECHO before
survivorship visit
Cardiology Consult
within 1‐2 weeks
EF < 50%, GLS < ‐17%,
CP, S/S of HF
DISCUSSION
Implemented cardiotoxicity risk assessment tool on May 1st 2017
• Implementation of the cardiotoxicity risk assessment tool has led to a 194% increase in referrals over 7 months.
• Has led to more awareness of cardiotoxicity and improved collaboration and communication among oncology and cardiology providers
• Both organizations demonstrate a high satisfaction with the implementation process and strongly support the development of cardiotoxicity prevention measures
REFERENCES• Barros-Gomes, S., Herrmann, J., Mulvagh, S.L., Lerman, A., Lin, G., & Villarraga, H.R., (2016). Rationale for setting up a cardio-
oncology unit: our experience at mayo clinic. Cardio-Oncology, 16(733). doi: 10.1186/s40959-016-0014-2• Bloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., & ... Butler, J. (2016). Cancer Therapy-Related Cardiac Dysfunction
and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circulation. Heart Failure, 9(1), e002661. doi:10.1161/CIRCHEARTFAILURE.115.002661
• Cardinale, D. & Cipolla, C.M. (2016). Chemotherapy-induced cardiotoxicity: importance of early detection. Expert Review of Cardiovascular Therapy. Retrieved from http://dx.doi.org/10.1080/14779072.2016.1239528
• Citro, R., Bossone, E., Kuersten, B., Gregorio, G., & Salustri, A. (2008). Tissue Doppler and strain imaging: anything left in the echo-lab?. Cardiovascular Ultrasound, 654. doi:10.1186/1476-7120-6-54
• Curigliano, G., Cardinale, D., Dent, S., Criscitiello, C., Aseyev, O., Lenihan, D., & Cipolla, C.M. (2016). Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA: A Cancer Journal for Clinicians, 66(4), 309-325. doi:10.3322/caac.21341
• Ewer, M.S. & Yeh, E. (2006) Cancer and the Heart. Hamilton, Ontario: BC Decker Inc.• Gulati, G., Heck, S. L., Geisler, J., Fagerland, M. W., Hoffmann, P., Gravdehaug, B., . . . Omland, T. (2016). EFFECT OF CANDESARTAN
AND METOPROLOL ON SUBCLINICAL MYOCARDIAL INJURY DURING ANTHRACYCLINE THERAPY: DATA FROM THE PREVENTION OF CARDIAC DYSFUNCTION DURING ADJUVANT BREAST CANCER THERAPY (PRADA) STUDY. Journal of the American College of Cardiology, 67(13), 1530. http://dx.doi.org.mtrproxy.mnpals.net/10.1016/S0735-1097(16)31531-5
• Hermann, J., Lerman, A., Sandhu, N.P., Villarraga, H.R., Mulvagh, S.L. & Kohli, M. (2014). Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Foundation for Medical Education and Research Clinical Proceedings. 89(9). (p. 1287-1306). dMeuth, C.L. & Lech, T.K. (2016) Drug list. In Yeh, E.T.H. MD Anderson Practices in Cardio-Oncology. Department of Cardiology, The University of Texas MD Anderson Cancer Center.oi.org/10.1016/j.mayocp.2014.05.013
REFERENCES• Luis Zamorano, J., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., & ... Suter, T. M. (2017). 2016 ESC
Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Journal Of Heart Failure. Supplements, 19(1), 9-42. doi:10.1002/ejhf.654
• Mulrooney, D. A., Yeazel, M. W., Kawashima, T., Mertens, A. C., Mitby, P., Stovall, M., & ... Leisenring, W. M. (2009). Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Studycohort. BMJ (Clinical Research Ed.), 339b4606. doi:10.1136/bmj.b4606
• Plana, J.C., Galderisi, M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, & … Lancellotti P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal of Cardiovascular Imaging 15(10). (p. 1063-93). doi: 10.1093/ehjci/jeu192.
• Pituskin, E., Mackey, J. R., Koshman, S., Jassal, D., Pitz, M., Haykowsky, M. J., & ... Paterson, D. I. (2017). Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity. Journal Of Clinical Oncology: Official Journal Of The American Society Of Clinical Oncology, 35(8), 870-877. doi:10.1200/JCO.2016.68.7830
• Shelburne, N., Adhikari, B., Brell, J., Davis, M., Desvigne-Nickens, P., Freedman, A., &… Remick, S. C. (2014). Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. Journal of The National Cancer Institute, 106(9), doi:10.1093/jnci/dju232
• Sulpher, J., Mathur, S., Graham, N., Crawley, F., Turek, M., Johnson, C., & ... Dent, S. (2015). Clinical experience of patients referred to a multidisciplinary cardiac oncology clinic: an observational study. Journal of Oncology, 20151-5. doi:10.1155/2015/671232